Long-term follow up data confirms the benefits of perioperative pembrolizumab in early-stage NSCLC
In the KEYNOTE-671, improvements in event-free survival and overall survival were observed after four years of follow up
Tiragolumab plus atezolizumab failed to improve overall survival in advanced non-squamous NSCLC
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
Mixed results for additional immunotherapy to standard care in stage III NSCLC
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Immunotherapy added to radiotherapy does not improve outcomes in early-stage NSCLC
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
New insights into pleural mesothelioma
Studies reveal promising evidence for the more precise tailoring of immunotherapy and the role of AI in improving response evaluation
Liquid biopsy plays a growing role in early-stage lung cancer
Research is moving forward to understand the value of this blood-based technology as a prognostic tool
Further support for durvalumab consolidation as a new standard of care in limited-stage SCLC
Subgroup analyses from the ADRIATIC study support previous practice-changing findings
Role of female leaders in addressing gender gaps in oncology
ESMO Women for Oncology Award Recipient Prof. Myung-Ju Ahn discusses gender equity in lung cancer research